KalVista Pharmaceuticals, Inc. (KALV) Company Overview

What does KalVista Pharmaceuticals do?

KalVista Pharmaceuticals developed oral medicines for rare diseases, ultimately concentrating on hereditary angioedema, or HAE. Its defining asset is EKTERLY, the brand name for sebetralstat, an oral plasma kallikrein inhibitor taken when an attack begins. The product differentiated itself from established injected or infused rescue therapies. KalVista’s official company site now identifies the company as part of Chiesi Group following the June 2026 acquisition.

Which patients and markets define the business?

HAE causes unpredictable swelling attacks involving the skin, abdomen, face, or throat. KalVista estimated prevalence at roughly one person in 35,000 to one in 50,000. The small population has urgent need, recurring attacks, specialist prescribers, and high reimbursement sensitivity. KalVista marketed EKTERLY directly in the United States and Germany and used partners in Japan and selected American markets, making this a focused rare-disease launch rather than a diversified drug portfolio.

How does KalVista make money?

KalVista had two revenue channels. The primary source was net EKTERLY product sales from direct markets such as the United States and Germany. Partnership and other revenue included product supplied to Kaken Pharmaceutical for Japan. KalVista retained manufacturing responsibility under that arrangement, which combined product supply with a mid-twenties effective royalty per unit.

Which revenue source mattered most in the latest quarter?

For the quarter ended March 31, 2026, product revenue was $39.2 million and partnership or other revenue was $1.7 million, producing $40.9 million total revenue. Product revenue represented 95.8% of the total. KalVista had become a commercial-product company, but nearly every valuation input still depended on EKTERLY demand and net pricing.

What determines the quality of that revenue?

Revenue quality depends on payer rebates, specialty-pharmacy economics, patient assistance, returns, and geography. Manufacturing cost was small relative to net selling price, but high gross margin did not create immediate profitability because KalVista was still funding sales, market access, medical affairs, and launch support. A DCF must therefore separate attractive unit economics from the time required to reach commercial scale.

What did KalVista’s latest reported quarter show?

KalVista’s latest standalone filing was its Form 10-Q for the quarter ended March 31, 2026. It showed both early product demand and the cost of launch: revenue reached $40.9 million, while selling, general and administrative expense reached $48.8 million.

How did the income statement change?

Why does customer concentration matter?

Four U.S. distribution customers represented 37%, 33%, 18%, and 11% of gross product revenue, leaving about 1% for others. This is channel concentration, not patient concentration, but it can amplify working-capital, ordering-pattern, and counterparty sensitivity.

Which turning points built the EKTERLY franchise?

KalVista’s history is a sequence of clinical, regulatory, commercial, and ownership de-risking events. Each changed the probability, timing, or ownership of future cash flows.

1. 2019-2023
   KalVista concentrated resources on oral plasma kallikrein inhibition for HAE, making route of administration the central product thesis rather than building a broad pipeline.
2. 2024
   The KONFIDENT Phase 3 program established rapid symptom relief and supported regulatory submissions. Financing during 2024 extended the runway into launch.
3. April-June 2025
   KalVista signed the Kaken agreement for Japan, adding supply-linked partner economics.
4. July 3, 2025
   The FDA approved EKTERLY for people aged 12 and older, creating the first U.S. oral on-demand treatment for HAE and triggering commercial launch.
5. Second half 2025
   European and other approvals expanded the addressable market, while the U.S. prescriber base reached 580 by December 31, 2025.
6. March 2026
   Positive interim KONFIDENT-KID data supported the plan to extend oral on-demand treatment to children aged 2 to 11.
7. June 11, 2026
   Chiesi completed the acquisition at $27 per share in cash, ending KALV’s public listing and transferring commercialization, development, and financing responsibility to a larger rare-disease platform.

What did launch adoption reveal?

KalVista’s eight-month fiscal 2025 results reported 1,702 U.S. patient start forms from launch through February 2026. Earlier, KalVista reported 580 unique prescribers through December 31, 2025 in its official launch update. The increase demonstrated demand, but start forms are not paid prescriptions or recognized revenue. They are an upper-funnel adoption KPI; net product revenue is the financial confirmation.

What gives EKTERLY a competitive advantage?

EKTERLY’s moat rests on its approved oral formulation, clinical evidence, patents and regulatory protections, specialist relationships, and launch know-how. An oral tablet reduces the friction of carrying, preparing, and administering an injectable rescue therapy. That convenience may support earlier and more consistent treatment.

What did the pivotal clinical program establish?

KONFIDENT enrolled 136 patients across 20 countries. Median time to beginning of symptom relief was 1.61 hours for the studied 300 mg dose, versus 6.72 hours for placebo. Real-world value still depends on access, patient behavior, and comparative experience.

Why is the moat defensible but not absolute?

First-mover status can create familiarity and preference, but it does not eliminate substitution. Prophylaxis can reduce attack frequency, injected rescue therapies have long experience, and new oral or genetic approaches may reshape the market. Durability depends on evidence, reimbursement, supply, pediatric expansion, and conversion of convenience into sustained net sales.

Who competes with KalVista in hereditary angioedema?

HAE competition spans prevention and rescue, and many patients use both. KalVista identified products from Takeda, CSL Behring, Pharming, BioCryst, and Ionis, plus programs from Pharvaris, Intellia, ADARx, and Argo. The strategic question is whether EKTERLY can become the preferred rescue option as prophylaxis improves.

Where does EKTERLY sit in the treatment architecture?

What does industry structure imply?

Payers have meaningful buyer power through prior authorization, step therapy, and formulary negotiation. Supplier power also matters because KalVista relied on third-party manufacturers. Entry barriers are high—clinical trials, approval, validated manufacturing, and specialist commercialization require capital—but rivalry remains intense. The structure combines high entry barriers with high product concentration and substitution risk.

How financially strong was KalVista before the acquisition?

KalVista entered the acquisition with substantial liquidity and significant claims on future cash flow. The transition report for the eight months ended December 31, 2025 showed $300.2 million of cash and marketable securities; the balance was $285.0 million at March 31, 2026. Liquidity was strong, but convertible notes and a royalty obligation would absorb value ahead of common equity in a standalone valuation.

What did the annual-style baseline reveal?

How should debt and royalty financing be interpreted?

At March 31, 2026, cash was $213.8 million and securities were $71.3 million. Convertible notes carried at $139.4 million had a 3.25% coupon and mature in 2031. A $132.8 million royalty obligation included a current portion and embedded derivative. The structure strengthened liquidity while reducing future cash flow available to owners.

Who owns KalVista now, and who owned KALV before the deal?

Chiesi Group now owns KalVista outright. The official acquisition-completion announcement, Chiesi reported that 77.8% of shares were tendered at $27 in cash. Remaining shares received the same consideration in the merger, after which KALV ceased Nasdaq trading.

What did the former shareholder base signal?

Before the deal, specialist healthcare funds and institutions dominated the shareholder base; no founder held majority voting control. KalVista’s 2025 proxy statement, based on 50,339,823 shares outstanding as of August 6, 2025, listed several holders near or above 5%. Such investors were familiar with binary clinical and commercial outcomes and could influence financing and strategic alternatives.

How did governance change?

Before acquisition, KalVista had a six-member classified board in three staggered classes; all directors except CEO Benjamin Palleiko were independent. After the merger, Chiesi can coordinate pricing, rollout, manufacturing, and development internally. That may improve execution, but external researchers receive less standalone disclosure than when KALV filed with the SEC.

Which growth drivers and KPIs matter most?

Growth depends on converting approvals into patient starts, starts into paid prescriptions, and U.S. adoption into global scale. Because attacks are episodic, no single daily-user metric explains revenue. The useful dashboard combines access, prescriber breadth, treatment behavior, pediatric progress, net sales, and commercial efficiency.

How large is the pediatric opportunity?

The KONFIDENT-KID interim update reported 172 treated attacks in 33 children as of December 15, 2025. Median treatment time was 25 minutes, and 67% were treated within the first hour. No serious or treatment-related adverse events were reported. Before acquisition, KalVista targeted a Q3 2026 filing and potential 2027 launch.

Where can Chiesi add value?

Chiesi adds a broader rare-disease platform, regulatory infrastructure, and capital base. It can reduce overhead duplication, accelerate access, and fund lifecycle studies without standalone financing. Value creation depends on preserving specialist focus while improving reimbursement, supply resilience, and geographic sequencing.

What risks could change the EKTERLY economics?

The main risks connect directly to revenue and cash flow. EKTERLY was the only commercial product, so slower adoption would affect sales, operating leverage, liquidity, and royalty-financing economics together. Third-party manufacturing and distribution also made quality or supply interruptions material despite high gross margins.

Which risk is most important after the Chiesi transaction?

Chiesi reduces standalone financing risk but introduces integration risk. Commercial teams, access contracts, supply arrangements, and development priorities must be combined without disrupting launch momentum. Public reporting has ended, so outside observers must rely on Chiesi disclosures, regulatory records, label changes, and clinical milestones rather than a separate KalVista quarterly package.

What is the key takeaway for valuation and research?

KalVista is no longer separately investable, so a current KALV price target is misplaced. The useful exercise is to understand why Chiesi paid $27 per share. A model begins with treated patients, attacks per patient, EKTERLY’s on-demand share, net revenue per attack, and geography, then estimates gross margin, operating leverage, label expansion, royalties, reinvestment, and terminal competition.

What should students and researchers monitor next?

• The pace at which cumulative patient starts convert into recognized net product revenue.
• Pediatric regulatory progress and the eventual commercial label for ages 2 to 11.
• International rollout, especially partner-market contribution and direct-market reimbursement.
• Whether product gross margin remains resilient as geography and channel mix broaden.
• Commercial operating leverage after integration into Chiesi’s rare-disease infrastructure.
• Competitive approvals that change rescue-treatment convenience or reduce attack frequency.
• How royalty obligations and acquisition accounting affect the economic return on EKTERLY.